Personalized Medicine

Five things for pharma marketers to know, Thursday, June 4

Five things for pharma marketers to know, Thursday, June 4

By

Novartis appeals the ban on its biosimilar Zarxio; AbbVie petitions for distinct biosimilar labels; Sanofi will study Toujeo in a real-world setting

Five things for pharma marketers to know: Wednesday, May 13

Five things for pharma marketers to know: Wednesday, May 13

By

FDA panel votes in favor of Vertex's combination cystic fibrosis drug; MannKind blames marketing on slow Afrezza sales; Orexigen draws ire after Contrave study terminated

Five things for pharma marketers to know: Thursday, March 26

Five things for pharma marketers to know: Thursday, March 26

By

Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk

Five things for pharma marketers to know: Friday, February 20

Five things for pharma marketers to know: Friday, February 20

By

23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.

Obama gives details on Precision Medicine Initiative

Obama gives details on Precision Medicine Initiative

By

President Barack Obama's recently unveiled Precision Medicine Initiative hopes to develop a new model of patient-driven research with the promise of accelerating biomedical discoveries and provide clinicians with new tools, knowledge, and therapies.

Five things for pharma marketers to know: Wednesday, January 21

Five things for pharma marketers to know: Wednesday, January 21

By By

President Barack Obama says personalized medicines need financial support in SOTU Address; Salix explores M&A options; lobbying groups PhRMA and BIO say generic painkillers without abuse-deterrent features should be pulled from shelves.

Five things for pharma marketers to know: Monday, December 22

Five things for pharma marketers to know: Monday, December 22

By

Express Scripts taps AbbVie hep. C drug as exclusive option; AZ first-in-class cancer drug approved; Cubist gains OK for superbug fighter.

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Illumina whittles genome cost to $1,000

The company's set of 10 sequencers brings down genome decoding to $1,000 each.

Regeneron doubles up on genetics

Regeneron doubles up on genetics

By

The company known for Eylea has launched a genetics discovery unit and teamed up with a partner to sequence 100,000 patient genomes.

Roche's bid to expand HPV test could edge out Pap

By

The diagnostic firm is looking to expand its Cobas HPV diagnostic into first-line use, possibly edging out the older Pap test.

Agency speeds Perjeta's bid to move into pre-op setting

By

The FDA granted the breast-cancer med "priority review" designation for use in an earlier line of therapy.

Myriad's loss a win for innovation, say the victors

Myriad's loss a win for innovation, say the victors

By

Merely isolating genes can't win you a patent, said the Supreme Court -- and that stands to fuel scientific inquiry in the age of personalized medicine

Novartis readying 2014 filing for lung cancer drug

Novartis readying 2014 filing for lung cancer drug

By

Novartis is advancing its "breakthrough" lung cancer drug into Phase III based on promising Phase I data.

GSK gets 2 cancer pills approved, but a deeper question is left unanswered

GSK gets 2 cancer pills approved, but a deeper question is left unanswered

By

GSK's newest cancer approvals highlight a problem that stalks progress with personalized medicines.

Myriad decision could be a drag on personalized medicine R&D

By

After a skeptical Supreme Court hearing, diagnostics and biopharma patent lawyers are sweating the outcome of Association for Molecular Pathology vs. Myriad Genetics, in which the Court could decide whether or not swatches of genes are patentable.

Still no jetpacks, but telemedicine, personalized medicine are the future, says study

By

Diabetes will be the 800-pound gorilla in healthcare for the foreseeable future, according to a crystal ball-gazing white paper from Euro RSCG which pegs the rise of telemedicine, a wave of "cyberchondria" and soaring rates of medical tourism as among the emerging trends reshaping the practice of medicine.

Pfizer effort urges lung cancer patients to get gene tests

Pfizer effort urges lung cancer patients to get gene tests

By

Pfizer Oncology has recruited Desperate Housewives and West Wing star Kathryn Joosten to feature in a national education campaign titled Lung Cancer Profiles, which aims to reduce stigma and plug molecular testing of the disease as the company deepens its investment in genetically-targeted oncology therapies.

Pfizer's Xalkori and Abbott test show promise in personalized medicine, companion diagnostics

By

The FDA's approval of Pfizer's Xalkori (crizotinib) represents a leap forward for both personalized medicine and Pfizer's R&D turnaround, but its commercial success hinges on a pricey diagnostic array by Abbott's Vysis.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.